Portal de investigación
Registro Español de Hidradenitis Supurativa.
Datos básicos
- Protocolo:
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2024
- Año de finalización:
Documentos
- No hay documentos
Participantes
Resultados del Ensayo Clínico
[[Translated article]]Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).
Couselo-Rodríguez C; (...); Flórez Á
Article. 10.1016/j.ad.2023.07.028. 2024
[[Translated article]]Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study.
Sanchez-Diaz, M; (...); Carrascosa-Carrillo, J M
Article. 10.1016/j.ad.2024.01.019. 2024
[Translated article] Fatal outcome in classic Kaposi's sarcoma.
Mansilla-Polo M, Botella-Estrada R
Article. 10.1016/j.ad.2024.03.015. 2024
A Case of Localised Immediate Hypersensitivity Reaction to Bimekizumab.
Lasheras-Perez, Miguel Antonio; (...); Ibanez-Echevarria, Ethel
Article. 10.1111/cod.14774. 2025
A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study
Puig, Lluis; (...); IMPULSE Investigators Grp
Article. 10.1159/000540019. 2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group
Sahuquillo-Torralba, Antonio; (...); Gallardo, Fernando
Article. 10.1111/ijd.17238. 2024
Correction: 'Lesion on the back of the hand in a hematopoietic stem cell transplant recipient'.
Mansilla-Polo M; (...); Botella-Estrada R
Correction. 10.1007/s15010-024-02259-0. 2024
Chikungunya fever with a positive tourniquet test: a novel description.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1093/ced/llae089. 2024
Delusional parasitosis (Ekbom's syndrome).
Mansilla-Polo, M, Martin-Torregrosa, D, Botella-Estrada, R
Article. 10.1016/j.semerg.2024.102423. 2024
Dermatologic Consultations for Patients Hospitalized in Non-Dermatologic Wards: Results of a 384-Patient Cross-Sectional Study From a Tertiary Referral Hospital
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.030. 2024
Dermatologic consultations for patients hospitalized in non-dermatologic wards: results of a 384-patient cross-sectional study from a tertiary referral hospital.
Mansilla-Polo, M; (...); Botella-Estrada, R
Case Reports. 10.1016/j.ad.2023.11.021. 2023
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
Mansilla-Polo M; (...); Botella-Estrada R
Letter. 10.1111/ddg.15502. 2024
Dermatological toxicities of talquetamab, a new bispecificantibody: case series and literature review
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Letter. 10.1111/ddg.15502_g. 2024
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
Daudén E; (...); Llamas-Velasco M
Article. 10.1111/ijd.16915. 2024
Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study
Lasheras-Pérez MA; (...); Rodríguez-Serna M
Article. 10.1111/ijd.17030. 2024
Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study
Duc Binh Phan; (...); Yiu, Zenas Zee Ngai
Meeting Abstract. 2024
Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study.
Phan, Duc Binh; (...); Yiu, Zenas Z N
Article. 10.1093/bjd/ljae454. 2024
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Magdaleno-Tapial, Jorge; (...); Martorell-Calatayud, Antonio
Article. 10.1155/2024/5528484. 2024
Erythema Elevatum Diutinum.
Mansilla-Polo M, Botella-Estrada R
Article. 10.1016/j.ad.2023.10.042. 2024
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.
Butrón-Bris B; (...); de la Fuente H
Article. 10.1111/exd.15152. 2024
Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1016/j.abd.2024.04.004. 2024
Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence.
Verdaguer-Faja, Julia; (...); Jaka, Ane
Article. 10.1111/jdv.20250. 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma
Gutzmer, Ralf; (...); Hauschild, Axel
Article. 10.1186/s12885-024-13101-z. 2024
Interparietal nodule in a 49-year-old woman.
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Case Reports. 10.1111/ddg.15398. 2024
Interparietaler Knoten bei einer 49-jährigen Frau
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Article. 10.1111/ddg.15398_g. 2024
'Lesion on the back of the hand in a hematopoietic stem cell transplant recipient'.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1007/s15010-024-02214-z. 2024
Melanoma and LEOPARD Syndrome: Understanding the Role of PTPN11 Mutations in Melanomagenesis.
Palacios-Diaz, Rodolfo David; (...); Botella-Estrada, Rafael
Article. 10.2340/actadv.v104.14720. 2024
Mohs micrographic surgery in immunosuppressed vs immunocompetent patients: Results of a prospective nationwide cohort study (REGESMOHS, Spanish registry of Mohs surgery).
Abril-Pérez C; (...); Botella-Estrada R
Article. 10.1111/jdv.20103. 2024
Nodular hidradenoma: Case report and brief literature review.
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Article. 10.1016/j.patol.2025.100801. 2025
One Dose Risankizumab Effectiveness in Psoriasis: A Real-Life Multicentre Study
Magdaleno-Tapial, Jorge; (...); Sanchez-Carazo, Jose Luis
Article. 10.1155/2024/4866592. 2024
Oral Ruxolitinib could Increase the Aggressiveness of Cutaneous Squamous Cell Carcinomas: A 6-Patient Series
Lasheras-Perez, M. A.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2023.07.035. 2025
Reactive arthritis.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1016/j.medcli.2023.08.017. 2023
Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study.
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Article. 10.1111/ajd.14339. 2024
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell A; (...); Magdaleno-Tapial J
Article. 10.1016/j.ad.2024.10.042. 2024
Recalcitrant Hailey-Hailey Disease With Satisfactory Response to Apremilast
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.025. 2024
Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Lasheras-Perez, Miguel A.; (...); Botella-Estrada, Rafael
Article. 10.1111/ijd.17339. 2024
Refractory cutaneous lupus erythematosus successfully treated with anifrolumab: a case series.
Martin-Torregrosa, Daniel; (...); Torres-Navarro, Ignacio
Letter. 10.1111/ijd.17022. 2024
Ruxolitinib for foreign body reaction to silicone in a patient with chronic graft-versus-host disease.
Palacios-Diaz, Rodolfo David; (...); Botella-Estrada, Rafael
Letter. 10.1111/ijd.17365. 2024
Ruxolitinib oral puede aumentar la agresividad de los carcinomas escamosos cutáneos: serie de 6 pacientes.
Lasheras-Perez MA; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.003. 2025
Safety of biosimilars compared with originator adalimumab for psoriasis: a multinational cohort study
Phan, Duc Binh; (...); Yiu, Zenas
Meeting Abstract. 10.1093/bjd/ljae360.068. 2024
Sarcoidosis cutánea tras inyecciones de plasma rico en plaquetas y maquillaje permanente de cejas.
Martín-Torregrosa D; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.043. 2024
Scaling and periorificial crusts in a pediatric patient.
Fayos-Gregori, Rafael; (...); Botella-Estrada, Rafael
Article. 10.1007/s15010-024-02309-7. 2024
Scalp Melanoma: A High-Risk Subset of Cutaneous Head and Neck Melanomas with Distinctive Clinicopathological Features.
Palacios-Diaz RD; (...); Botella-Estrada R
Article. 10.3390/jcm12247643. 2023
Skin cancer risk after hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1111/ijd.17371. 2024
Skin lesions in a lung transplant recipient
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Editorial Material. 10.1016/j.eimc.2023.09.005. 2024
Skin lesions in a lung transplant recipient.
Mansilla-Polo M; (...); Botella-Estrada R
Case Reports. 10.1016/j.eimce.2023.09.005. 2024
Study of Microsatellite Instability by Immunohistochemistry in a Cohort of Patients With Melanoma
Diaz, Rodolfo David Palacios; (...); Estrada, Rafael Botella
Article. 10.1111/cup.14758. 2025
Successful treatment of erythema nodosum leprosum with upadacitinib and roflumilast.
Mansilla-Polo, Miguel; (...); Torres-Navarro, Ignacio
Letter. 10.1111/ijd.17293. 2024
Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib: Evidence From 2 Cases.
Martin-Torregrosa, Daniel; (...); Botella-Estrada, Rafael
Article. 10.1001/jamadermatol.2024.4582. 2024
Successful Treatment of Stimulator of Interferon Genes-Associated Vasculopathy of Infantile Onset SAVI Syndrome With Anifrolumab.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1001/jamadermatol.2024.2160. 2024
Tattoo-Associated Common Wart
Mansilla-Polo, M., Llavador-Ros, M., Botella-Estrada, R.
Editorial Material. 10.1016/j.ad.2024.05.001. 2024
Treatment of palmoplantar psoriasis with oral roflumilast: a case series.
Lasheras-Perez, Miguel Antonio; (...); Botella-Estrada, Rafael
Article. 10.1093/ced/llae229. 2024
Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial.
Perez-Del-Caz, Maria Dolores; (...); Perez-Plaza, Aranzazu
Article. 10.1016/j.burns.2025.107427. 2025